This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Cheap Biotech Stocks That Could Soar

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Neptune Technologies and Bioresources (NEPT - Get Report)

If swallowing medicinal-grade fish oil pills lowers blood levels of harmful lipids, raises good cholesterol while not elevating levels of bad cholesterol, then pills filled with krill oil -- derived from crushing those tiny, shrimp-like crustaceans that whales eat by the ton -- might be just as good if not better.

Neptune admirers see the company as the next Amarin (AMRN), which investors have bid up to great heights based on the blockbuster potential of AMR101, a new medicinal-grade fish oil, or Ethyl EPA, pill that will soon be filed with U.S. regulators.

Neptune is developing a pharmaceutical-grade krill oil pill. A small study showed krill oil to be superior to fish oil in lowering lipids and bad cholesterol but it was published in an alternative medicine journal in 2004 so basically, no one believes the results. Neptune is planning to conduct a new phase II study of its krill oil pill with results expected next year.

On top of that, Neptune operates a profitable nutraceutical business that sells a consumer formulation of krill oil, with revenue of $16.7 million in its last fiscal year. Neptune is also partnering with food companies to have krill oil added as a nutritional ingredient.
3 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ASTM $3.10 -0.18%
DSCI $3.12 0.00%
CYCC $0.33 6.80%
CLSN $1.11 2.80%
GTXI $0.70 0.01%


Chart of I:DJI
DOW 15,884.29 +224.11 1.43%
S&P 500 1,855.79 +26.71 1.46%
NASDAQ 4,317.4520 +50.6150 1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs